Second Quarter 2024
** Total revenue increased 12 per cent, 11 per cent at constant exchange rates, (CER)1, to
** Haematology revenue increased 13 per cent at CER to
** Immunology revenue increased 7 per cent at CER to
** Revenue from medicines in the strategic portfolio1 grew by 74 per cent at CER to
** The adjusted EBITA margin1,2 was 28 per
** Earnings per share (EPS) before dilution was
** Altuvoct® (efanesoctocog alfa) was EU approved for once-weekly treatment of haemophilia A
** Aspaveli was EU approved for use among treatment naïve adult patients with PNH
** Biologics license application to FDA initiated for SEL-212 for the potential treatment of chronic refractory gout
Outlook 2024 - updated
** Revenue is anticipated to grow by low double-digit percentage at CER (previously high single-digit)
** The adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue (unchanged)
1. Alternative Performance Measures (APMs). |
2. Items affecting comparability (IAC). |
3. Comparatives have been adjusted to consider the bonus issue element in the rights issue carried out in 2023. |
The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding
|
Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
For other countries, please find the details here.
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on
Head of Investor Relations
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q2-2024-report--strong-delivery-driven-by-robust-portfolio-performance,c4015301
https://mb.cision.com/Main/14266/4015301/2916924.pdf
(c) 2024 Cision. All rights reserved., source